The global corneal ulcer treatment market is valued at US$ 1.10 billion in 2026 and is projected to reach US$ 1.56 billion by 2033, growing at a 5.1% CAGR.
Market growth is driven by earlier specialist referrals for corneal ulcers and the rising global prevalence of diabetes-related ocular complications.
Bacterial Ulcers lead the market with a 39.8% share, supported by their high incidence and the immediate initiation of treatment in clinical practice.
North America dominates the market with a 37.6% share in 2026, backed by advanced ophthalmology infrastructure and strong reimbursement support for premium therapies.
A major opportunity lies in AI-powered remote screening and diagnosis tools, particularly in underserved regions with limited access to ophthalmology specialists.